<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513509</url>
  </required_header>
  <id_info>
    <org_study_id>202006205RIND</org_study_id>
    <nct_id>NCT04513509</nct_id>
  </id_info>
  <brief_title>Rate Control in Patients With Atrial Fibrillation</brief_title>
  <acronym>RaP-AF</acronym>
  <official_title>The Surrogate Marker of Rate Control in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To search for the best marker for the patients in atrial fibrillation with rate control&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an aging society, the prevalence of atrial fibrillation is increasing. The main treatment&#xD;
      strategy is to reduce the complications of embolic stroke and heart failure. Among these&#xD;
      patients, a group of them will choose to have &quot;rate control&quot; based on the heart conditions&#xD;
      and the preference of the patients. The strategy is to control the ventricular rate by drugs&#xD;
      to prevent the heart from failure. However, when the physicians attempt to do so, they&#xD;
      encounter two questions: how much is the optimal drug dose? And what is the best marker we&#xD;
      are looking to? To answer these questions, the investigators design a prospective, cross-over&#xD;
      study to explore this issue. The participants will do cardiopulmonary exercise test (CPET)&#xD;
      before and after treatment. They will receive another CPET if drug dose is titrated up. With&#xD;
      the study, the investigators will understand whether a resting heart rate can be a good&#xD;
      marker for optimal drug dosage, and what is the optimal range of heart rate the physicians&#xD;
      should target.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 7, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Maximal Oxygen consumption</measure>
    <time_frame>0, 3, 6 months</time_frame>
    <description>acquire the data by Cardiopulmonary exercise test (CPET) with different (low and high) drug dosages for rate control</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Rate Control</condition>
  <condition>Cardiopulmonary Exercise Test</condition>
  <arm_group>
    <arm_group_label>rate control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin</intervention_name>
    <description>Start with empirical lower dose for 3 months, and then titrate up</description>
    <arm_group_label>rate control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20~90 years old&#xD;
&#xD;
          2. Rate control is preferred after shared decision making&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. cannot cooperate with or complete CPET&#xD;
&#xD;
          2. has contraindication for CPET, such as uncontrolled heart failure, hypertension,&#xD;
             angina, valvular heart disease, lung function impariment that SaO2&lt;90% at room air.&#xD;
&#xD;
          3. Ventricular rate below 80/min before any medication&#xD;
&#xD;
          4. Permanent pacemaker implanted&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Chieh Yu, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chih-Chieh Yu, MD.PhD</last_name>
    <phone>+886-2-23123456</phone>
    <phone_ext>65257</phone_ext>
    <email>sweetchieh@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chih-Chieh Yu, MD.PhD.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65257</phone_ext>
      <email>sweetchieh@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>rate control</keyword>
  <keyword>cardiopulmonary exercise test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Bisoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

